Guided Therapeutics (GTHP) EBT Margin (2010 - 2025)
Guided Therapeutics recorded quarterly EBT Margin of 206.44% in Q4 2025, up 83.31% quarter-over-quarter from 1236.67% in Q3 2025, and up 6499356.0% year-over-year from N/an in Q4 2024.
Guided Therapeutics' EBT Margin history runs 16 years deep, the most recent figure standing at 206.44% for Q4 2025.
- In Q4 2025, EBT Margin rose 6499356.0% year-over-year to 206.44%; the TTM figure through Dec 2025 stood at 416.95% (up 3411162.0% YoY), while the FY2025 annual figure was 416.69%, up 3411188.0% from the prior year.
- EBT Margin came in at 206.44% for Q4 2025 at Guided Therapeutics, up from 1236.67% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 357.89% in Q3 2021 to a low of 65200.0% in Q4 2024.
- A 5-year average of 14300.47% and a median of 3744.32% in 2023 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin sank 6399375 bps in 2024 and jumped 6499356 bps in 2025, its largest moves.
- Guided Therapeutics' EBT Margin stood at 740.0% in 2021, then sank by 4864 bps to 36733.33% in 2022, then jumped by 97 bps to 1206.25% in 2023, then slumped by 5305 bps to 65200.0% in 2024, then surged by 100 bps to 206.44% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 206.44%, 1236.67%, and 693.16% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 15.57% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 27.84% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 4.87% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 22.61% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 9.84% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.17% |
| 10 | Guided Therapeutics | - | - | 458,000.00 | -206.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -206.44% |
| Sep 30, 2025 | -1,236.67% |
| Jun 30, 2025 | -693.16% |
| Dec 31, 2024 | -65,200.00% |
| Mar 31, 2024 | -6,700.00% |
| Dec 31, 2023 | -1,206.25% |
| Jun 30, 2023 | -3,538.64% |
| Mar 31, 2023 | -3,950.00% |
| Sep 30, 2022 | -36,733.33% |
| Jun 30, 2022 | -18,520.00% |
| Mar 31, 2022 | -10,140.00% |
| Dec 31, 2021 | -740.00% |
| Sep 30, 2021 | 357.89% |
| Jun 30, 2021 | -51,700.00% |
| Dec 31, 2020 | 8,664.00% |
| Sep 30, 2020 | 2,045.45% |
| Dec 31, 2019 | 6,768.75% |
| Sep 30, 2019 | -12,600.00% |
| Jun 30, 2019 | -266,300.00% |
| Mar 31, 2019 | -1,194.44% |
| Dec 31, 2018 | -6,528.57% |
| Sep 30, 2018 | -37,300.00% |
| Jun 30, 2018 | 42,750.00% |
| Mar 31, 2018 | 27,050.00% |
| Dec 31, 2017 | -8,164.49% |
| Sep 30, 2017 | -7,166.67% |
| Jun 30, 2017 | -1,231.03% |
| Mar 31, 2017 | -509.52% |
| Dec 31, 2016 | 413.58% |
| Sep 30, 2016 | -222.11% |
| Dec 31, 2015 | -19,533.33% |
| Sep 30, 2015 | -27,387.50% |
| Jun 30, 2015 | -17,060.00% |
| Mar 31, 2015 | -8,300.00% |
| Dec 31, 2014 | 127,446.15% |
| Sep 30, 2014 | -13,509.09% |
| Jun 30, 2014 | -19,563.64% |
| Mar 31, 2014 | 8,221.05% |
| Dec 31, 2013 | 639.60% |
| Sep 30, 2013 | 1,672.09% |
| Jun 30, 2013 | 788.29% |
| Mar 31, 2013 | 1,086.83% |
| Dec 31, 2012 | 117.29% |
| Sep 30, 2012 | 142.28% |
| Jun 30, 2012 | -127.54% |
| Mar 31, 2012 | 141.09% |
| Dec 31, 2011 | 308.15% |
| Sep 30, 2011 | 260.63% |
| Jun 30, 2011 | 54.33% |
| Mar 31, 2011 | 94.65% |
| Jun 30, 2010 | -62.48% |